As of June 20, 2025, Vifor Pharma AG (VIFN.SW) reports a Gross Margin of 61.70%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Vifor Pharma AG's Gross Margin
Over recent years, Vifor Pharma AG's Gross Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2021-12-31 | 61.70% |
| 2020-12-31 | 58.89% |
| 2019-12-31 | 59.43% |
| 2018-12-31 | 59.06% |
| 2017-12-31 | 59.91% |
This slight upward trend highlights how Vifor Pharma AG manages its operational efficiency and pricing power over time.
Comparing Vifor Pharma AG's Gross Margin to Peers
To better understand Vifor Pharma AG's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Vifor Pharma AG (VIFN.SW) | 61.70% |
| Vectura Group PLC (VEC.L) | 5320.04% |
| Financiere de Tubize SA (TUB.BR) | 99.96% |
| Camurus AB (CAMX.ST) | 93.07% |
| Indivior PLC (INDV.L) | 85.27% |
| Cosmo Pharmaceuticals NV (COPN.SW) | 83.00% |
Compared to its competitors, Vifor Pharma AG's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.